Release Summary

Spectrum Pharmaceuticals announced safety findings from the pivotal, registrational Phase 2 BELIEF trial of belinostat, a pan-histone deacetylase (HDAC) inhibitor at T-Cell Lymphoma Forum.

Spectrum Pharmaceuticals